Amgen And Array Enter Development Agreement

Amgen Inc. (Nasdaq: AMGN) and Array BioPharma Inc. (Nasdaq: ARRY) will jointly develop a type 2 diabetes treatment. Shares of Array leaped 53 cents to close at $2.78 while Amgen stock fell $1.11 to close at $55.75.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.